BIAF

Research suggests a potential topical treatment for common skin cancers, squamous cell and basal cell carcinoma Findings will be presented at 2026 RNA Therapeutics Symposium June 24-26 bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, will present preclinical findings for a novel therapeutic approach that uses small interfering RNAs (siRNAs) that kill squamous and basal skin cancer cells in vitro while leaving non-cancerous skin cells unharmed. The newly released findings support the Company’s efforts to develop topical treatments for squamous cell and basal cell carcinoma, two of the most

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced the closing of its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.The offering consisted of 4,000,000 shares of its common stock, par value $0.007 per share (or pre-funded warrants in lieu thereof) at a purchase price of $0.80 per share (or $0.793 per pre-funded warrant). Each pre-funded warrant will be exercisable for

424B4 - bioAffinity Technologies, Inc. (0001712762) (Filer)

JERSEY CITY, N.J., June 17, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, priced a Public Offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company. The offering consists of 4,000,000 shares of its common stock, par value $0.007 per share (or pre-funded warrants in lieu thereof

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced that it has priced a Public Offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company. The offering consists of 4,000,000 shares of its common stock, par value $0.007 per share (or pre-funded warrants in lieu thereof) at a purchase price of $0.80 per share (or $0.793 per pre-funded warrant). Each pre-funded warrant will be exercisable for one share of co

EFFECT - bioAffinity Technologies, Inc. (0001712762) (Filer)

S-1/A - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Expert panel will share real-world case studies to demonstrate how mobile CT screening, noninvasive CyPath® Lung testing, and comprehensive functional lung imaging can reduce cost while improving access, early detection and outcomes for veterans National Association of Veterans' Research and Education Foundations (NAVREF) to host July 21 webinar Register here bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, announced a webinar on July 21, 2026, featuring clinical experts discussing emerging approaches to lung health screening and earl

S-1 - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Interventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in their practices CyPath® Lung has demonstrated the ability to aid in the detection of early-stage lung cancer and support surveillance of cancer survivors for recurrence bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced the Society for Advanced Bronchoscopy (SAB) will host a webinar on CyPath® Lung's expanding role in pulmonary, oncology and surgical practices for the detection and management of early-stage lung cancer. The live

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Strong intellectual property portfolio helps build shareholder value Patent strategy protects CyPath® Lung's flow cytometry-driven diagnostic approach in international markets bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the Mexican Institute of Industrial Property for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. Upon issuance, the Mexican patent application will protect the use of defined antibod

S-8 - bioAffinity Technologies, Inc. (0001712762) (Filer)

424B3 - bioAffinity Technologies, Inc. (0001712762) (Filer)

EFFECT - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

CyPath® Lung unit sales in April increased nearly 300% compared to April 2025 Increasing unit sales for CyPath® Lung continues first quarter 2026 trend of accelerating adoption and clinical use Noninvasive test has potential to transform lung cancer risk assessment and nodule management bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath® Lung diagnostic test achieved a record high in a single month and increased nearly 300% in April 2026 compared to the same period in 2025, based on preliminary unaudited data. The strong CyPath® Lung unit sales growt

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

CyPath® Lung cancer diagnostic unit sales rise 146% year-over-year Growth expected to accelerate throughout 2026 as planned commercial initiatives seek to drive increasing awareness of CyPath® Lung benefits bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the first quarter ended March 31, 2026. Q1 2026 Highlights CyPath® Lung unit sales increased 146% year-over-year in the first quarter of 2026, reflecting accelerating physician adoption and expanding clinical use of the Company's noninvasive lung

S-1 - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)